載入中
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
一般交易時段
US$4.905
−US$0.015 · -0.30%
盤中時間採用ET。市場資料可能有所延遲。
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
日內區間
目前US$4.905
52週區間
目前US$4.905
盤中時間採用ET。市場資料可能有所延遲。
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
日內區間
目前US$4.905
52週區間
目前US$4.905
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 24.5萬 USD | 7802.9萬 USD | 4426.2萬 USD | 2787.9萬 USD | 2899.1萬 USD |
| 毛利 | −24.5萬 USD | −7802.9萬 USD | −4426.2萬 USD | −2787.9萬 USD | −2899.1萬 USD |
| 研究與開發 | 8140.4萬 USD | 7802.9萬 USD | 4426.2萬 USD | 2787.9萬 USD | 2899.1萬 USD |
| 銷售、一般及管理費用 | 4205.6萬 USD | 2503.7萬 USD | 1566.8萬 USD | 1092.9萬 USD | 1235萬 USD |
| 營業費用 | 1.23億 USD | 2516.7萬 USD | 1574.5萬 USD | 1096萬 USD | 1248.6萬 USD |
| 利息收入 | 416.2萬 USD | 646.7萬 USD | 443.6萬 USD | 88 USD | 2282 USD |
| 利息支出 | — | — | — | 8.8萬 USD | 228.2萬 USD |
| 折舊和攤銷 | 8.7萬 USD | 13萬 USD | 7.7萬 USD | 16.7萬 USD | 36.7萬 USD |
| 營業利益 | −1.24億 USD | −1.03億 USD | −6000.7萬 USD | −3883.9萬 USD | −4147.7萬 USD |
| 淨利 | −1.19億 USD | −9588.1萬 USD | −5469.8萬 USD | −3815萬 USD | −4301.4萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.00
上漲空間 103.87%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3322.91萬0.00%2.3兆 USD0.03%US$381.8-0.04%
iShares Russell 2000 ETFIWM1969.49萬0.03%787.4億 USD0.19%US$278.63-0.11%
State Street SPDR S&P Biotech ETFXBI1558.45萬0.16%98.74億 USD0.35%US$152.62-0.75%
Vanguard Extended Market ETFVXF856.59萬0.01%954億 USD0.05%US$234.45-0.23%
iShares Russell 2000 Growth ETFIWO690.74萬0.05%139.17億 USD0.24%US$354.99-0.50%
Vanguard Russell 2000 ETFVTWO473.51萬0.03%180億 USD0.06%US$112.55-0.10%
iShares Biotechnology ETFIBB392.64萬0.04%108.2億 USD0.44%US$205.38-0.54%
Schwab U.S. Small-Cap ETFSCHA390.03萬0.02%218.24億 USD0.03%US$32.7801-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
